COVID-19 treatment
-
April 11, 2023
VUMC-led trial shows two investigational drugs are ineffective for treating severe COVID-19
A Vanderbilt-led study evaluating two investigational drugs to treat severe COVID-19 demonstrated that neither drug was effective. -
April 10, 2023
Updated COVID-19 infection prevention guidelines for all VUMC workforce members
-
April 10, 2023
Updated guidance on masking, COVID-19 testing at VUMC
-
January 5, 2023
VUMC-led COVID-19 clinical trial platform goes international
The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally. -
January 4, 2023
VUMC strongly recommends COVID-19 bivalent booster vaccination as new COVID-19 variants appear in our region
With the development of new variants of the COVID-19 virus across the U.S. and the world, Vanderbilt University Medical Center recommends getting the bivalent booster vaccination. -
November 10, 2022
AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17
On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals. -
November 3, 2022
Event to spotlight VUMC’s COVID-19 research efforts
The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.